Atypical Mole Syndrome and Dysplastic Nevi: Identification of Populations at Risk for Developing Melanoma - Review Article

Total Page:16

File Type:pdf, Size:1020Kb

Atypical Mole Syndrome and Dysplastic Nevi: Identification of Populations at Risk for Developing Melanoma - Review Article CLINICS 2011;66(3):493-499 DOI:10.1590/S1807-59322011000300023 REVIEW Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article Juliana Hypo´ lito Silva,I Bianca Costa Soares de Sa´,II Alexandre Leon Ribeiro de A´ vila,II Gilles Landman,III Joa˜ o Pedreira Duprat NetoII I Oncology School Celestino Bourroul - Hospital AC Camargo, Sa˜ o Paulo, SP, Brazil. II Skin Oncology Department - Hospital AC Camargo - Sa˜ o Paulo, SP, Brazil. III Pathology Department - Hospital AC Camargo - Sa˜ o Paulo, SP, Brazil. Atypical Mole Syndrome is the most important phenotypic risk factor for developing cutaneous melanoma, a malignancy that accounts for about 80% of deaths from skin cancer. Because the diagnosis of melanoma at an early stage is of great prognostic relevance, the identification of Atypical Mole Syndrome carriers is essential, as well as the creation of recommended preventative measures that must be taken by these patients. KEYWORDS: Dysplastic Nevus Syndrome; dysplastic nevi; melanoma; early diagnosis; Risk Factors. Silva JH, de Sa´ BC, Avila ALR, Landman G, Duprat Neto JP. Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics. 2011;66(3):493-499. Received for publication on November 23, 2010; First review completed on November 24, 2010; Accepted for publication on November 24, 2010 E-mail: [email protected] Tel.: 55 11 2189-5135 INTRODUCTION Several studies have shown that the presence of dysplas- tic nevi considerably increases the risk of developing The incidence of cutaneous melanoma has increased melanoma, which demonstrates that these lesions, aside rapidly worldwide.1-5 Although it corresponds to only 4% of 4 from being precursors to disease are also important risk all skin cancers, it accounts for 80% of skin cancer deaths. 4,7,14-19 markers. Nevertheless, the risk magnitude varies Because early detection of the disease is implicit in its cure 3,4,15,16,20 among patients with this type of pigmented lesion. and only 14% of patients with metastatic disease survive 4-6 There are still controversies in the literature regarding the beyond 5 years, knowledge of factors that increase an nomenclature, clinical definition, dermoscopic characteris- individual’s risk for developing melanoma and diagnosis at tics and histopathological, genetic and molecular patterns of an early stage of the disease have great prognostic dysplastic nevi.4,8 relevance. In this literature review of dysplastic nevi and AMS, we The risk factors for developing melanoma are both genetic demonstrate the importance of a complete dermatological and environmental, especially the presence of multiple examination for the evaluation and monitoring of patients melanocytic nevi, dysplastic nevi and atypical mole syn- with dysplastic nevi and AMS and suggest criteria for drome (AMS), as the main clinical phenotypic susceptibil- 4-9 follow-up. ity. In 1820, Norris10 described what is currently considered in a family predisposed to melanoma. In 1978, Clark11 Epidemiology reported an increased incidence of cutaneous melanoma in Dysplastic nevi are relatively common in the general 8 families with multiple melanocytic lesions, introducing the population. Reports have described the prevalence ranging melanoma tumor progression model from melanocytic from 2% to 53% in different studies, depending on the 8 nevi.11,12 At the time, Clark used the term B-K mole syndrome diagnostic criteria (clinical or histological). A more accurate using the initials of the patients surnames.11 Currently, the estimate is considered to be about 2%-8% of Caucasians, terms AMS, Dysplastic Nevus Syndrome and Familial with a predilection for young individuals (less than 30 to 40 18 Atypical Multiple-Mole Melanoma Syndrome (FAMMM) years of age). The frequency of dysplastic nevi in patients 18 have been employed.12 In 1985, Elder13 extended the theory with a history of melanoma is much higher: 34% to 59%. of ‘‘nevus-melanoma’’ for sporadic dysplastic nevi as a Evidence suggests that sun exposure, in addition to genetic possible precursor to sporadic melanoma. susceptibility, may increase the appearance of such nevi.1,8,18 Data concerning the prevalence of AMS are difficult to Copyright ß 2011 CLINICS – This is an Open Access article distributed under document in part due to the large variability in the the terms of the Creative Commons Attribution Non-Commercial License (http:// diagnostic criteria employed by different studies. Based on creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the estimates by the National Institutes of Health (NIH), it has original work is properly cited. been estimated that about 32,000 individuals were carriers 493 CLINICS 2011;66(3):493-499 Silva JH et al. of AMS and familial melanoma in the United States in 1985, while about 4 million had sporadic AMS.3,21 Genetics AMS can be sporadic or hereditary, in which case autosomal dominant inheritance is suggested with variable expressivity and incomplete penetrance.22 To date, no susceptibility gene has been identified for this syndrome.22 However, there are reports of associations between devel- opment of AMS and changes in chromosomes 9p21 and 1p36.23 It was demonstrated that the presence of dysplastic nevi increases the risk of melanoma in patients with Figure 1 - Macroscopic image of two melanocytic lesions whose germline mutations in CDKN2A, the main genomic locus characteristics are superimposed by the ABCD rule (asymmetry, of melanoma susceptibility.24,25 This genomic locus harbors irregular borders, varied coloration, diameter greater than two important genes involved in cell cycle control, 6 mm): Left - dysplastic nevus; Right – cutaneous melanoma. senescence and apoptosis: p16 and p14ARF. The presence of a susceptibility gene for the development of dysplastic known that the atypical nevus can evolve from a seemingly nevi was also observed on chromosome 7q21.3 in patients common melanocytic nevus or show atypical features from with the p16 gene mutation in four families with familial its first emergence.27 As dynamic lesions, they may become melanoma.20 progressively more or less atypical in their clinical aspect.27 A high incidence of somatic mutations of the BRAF gene Although the majority of dysplastic nevi remain stable, has also been detected in patients with dysplastic nevi and regress over time or evolve benignly, monitoring of these primary melanomas.8 Moreover, melanocytic lesions of lesions is essential. Their prophylactic excision is not rapid growth or development are more likely to have justified.8,27 mutations in this gene when compared to lesions without a AMS has already been described by several authors and history of changes in their clinical aspects.8 institutions based on clinical characteristics of patients and Other genetic changes described in dysplastic nevi their personal and/or family history of melanoma, with or include microsatellite instability, loss of heterozygosity without histopathological confirmation of an atypical 12 (LOH) and increased activity of the telomerase enzyme. nevus.3 Currently, it is known that only 20% to 30% of melanomas According to Newton et al.1, AMS can be defined through arise in association with a melanocytic nevus, which a scoring system, assigning one point for each feature, as indicates that the Clark’s theory of progression can explain seen in Table 1. Patients with scores greater than or equal to only one of the paths from carcinogenesis to melanoma.26 Patients with dysplastic nevi may have a reduced ability 8 to repair UV-induced DNA damage. Table 1 - AMS classifications and their specific Although genetic and environmental interactions are characteristics. clearly involved in the melanocytic transformation patho- genesis, the understanding of its molecular mechanisms still CLASSIFICATION CHARACTERISTICS COMMENTS remains incomplete.8 Newton et al. 1) two or more clinically atypical Scores greater (1993) nevi, 2) more than 100 nevi in than or equal Clinical Diagnosis patients between 20 and 50 years to 3 Clinically, a dysplastic nevus is most often a spotted of age, 3) more than 50 nevi in characterize lesion of 5 mm or more in diameter, with irregular and patients under 20 years of age or the AMS poorly defined borders and variable shades of brown, and it more than 50 years of age, 4) phenotype. more than one nevus in buttocks may present a reddish hue, with bleaching accomplished 18 or instep, 5) nevi on the anterior using vitropressure. It often presents a central papule, scalp, 6) one or more pigmented surrounded by a pigmented macular ring, giving the lesions in the iris. appearance of a ‘‘fried egg’’.18 Thus, there is considerable Classical (1990) 1) 100 or more melanocytic nevi, Requires all overlap with the ABCDE rule used for clinical diagnosis of 2) one or more melanocytic features for melanoma, namely, A: asymmetry, B: irregular borders C: nevi greater than or equal to diagnosis. High 8mm in its largest diameter, demand for varied colors, D: diameter . 6 mm and E: elevation and 3) one or more clinically total count of (simultaneous presentation of macular and papular compo- atypical melanocytic nevi nevi for 3,12,18 nents) (Figure 1). classification; Dysplastic nevi may be present in any topography, low sensitivity including double-covered areas (such as buttocks and National 1) occurrence of melanoma
Recommended publications
  • Critical Evaluation of the So-Called “Junction Nevus”
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector CRITICAL EVALUATION OF THE SO-CALLED "JUNCTION NEVUS* S. WILLIAM BECKER, MS., M.D. The serious study of pigmented nevi was undertaken by many workers in the closing years of the 19th Century. All recognized that the microscopic picture of nevi differed from anything seen in other organs. The presence of nevus cells in both the epidermis and dermis led to concepts of origin at one or the other site, or at both sites. Dermal Origin: Demieville (1) believed that the nevus cells arose from adven- titial and endothelial cells of blood vessels. Bauer (2) and vonRecklinghausen (3) thought that the origin was from endothelium of lymph vessels rather than of blood vessels. Epidermal Origin: According to Abesser (4), Duranti, in 1871, was the first to suggest an epidermal origin of nevus cells. Kromayer (5) stated that the endo- thelium-like cells originate in the basal portion of the epidermis as "Bläschen- zellen", migrate to the dermis and develop connective tissue and elastic fibers, a change which he called "desmoplasia". Abesser (4) agreed that the cells origi- ated in the epithelium and lost their intercellular bridges, but migrated into the dermis as epithelium-like cells, and remained such. Unna (6) advanced the concept that the epithelial cells changed by losing their intercellular bridges and multiplied in groups, a process which he called "Ab- sonderung", then migrated as groups to the dermis, which he called "Abtrop- fung", thus forming pigmented nevi.
    [Show full text]
  • Digital Epiluminescence Microscopy Monitoring of High-Risk Patients
    STUDY Digital Epiluminescence Microscopy Monitoring of High-Risk Patients June K. Robinson, MD; Brian J. Nickoloff, MD, PhD Objective: To examine the outcome of digital epilumi- dence in and comfort with dermatologic surveillance and nescence microscopic (DELM) surveillance of atypical skin self-examination performance were assessed. nevi in a high-risk population for 4 years. Results: During annual surveillance with DELM, 5.5% of Design: Atypical, flat melanocytic lesions in 100 pa- the lesions changed. Among the 193 excisional biopsy speci- tients at high risk of developing melanoma were fol- mens there were 4 melanomas in situ, 169 dysplastic nevi, lowed annually with DELM. Pigmentary changes or an and 20 common nevi. Confidence in and comfort with sur- increase in DELM diameter of 1 mm or greater was an veillance and skin self-examination improved after DELM. indication to perform an excisional biopsy. Conclusions: The criteria applied to detect substantial Setting: Cardinal Bernardin Cancer Center Melanoma DELM changes were an increase in DELM diameter of 1 Program, Loyola University Health System, Maywood. mm or greater and pigmentary changes, including ra- dial streaming, focal enlargement, peripheral black dots, Patients: A consecutive sample of 3482 lesions from 100 and “clumping” within the irregular pigment network. patients (aged 18-65 years) with at least 2 images of the Use of DELM enhanced confidence in and comfort with same lesion. care, which extended to performing more extensive skin self-examination. Main Outcome Measures:
    [Show full text]
  • Melanomas Are Comprised of Multiple Biologically Distinct Categories
    Melanomas are comprised of multiple biologically distinct categories, which differ in cell of origin, age of onset, clinical and histologic presentation, pattern of metastasis, ethnic distribution, causative role of UV radiation, predisposing germ line alterations, mutational processes, and patterns of somatic mutations. Neoplasms are initiated by gain of function mutations in one of several primary oncogenes, typically leading to benign melanocytic nevi with characteristic histologic features. The progression of nevi is restrained by multiple tumor suppressive mechanisms. Secondary genetic alterations override these barriers and promote intermediate or overtly malignant tumors along distinct progression trajectories. The current knowledge about pathogenesis, clinical, histological and genetic features of primary melanocytic neoplasms is reviewed and integrated into a taxonomic framework. THE MOLECULAR PATHOLOGY OF MELANOMA: AN INTEGRATED TAXONOMY OF MELANOCYTIC NEOPLASIA Boris C. Bastian Corresponding Author: Boris C. Bastian, M.D. Ph.D. Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology Departments of Dermatology and Pathology University of California, San Francisco UCSF Cardiovascular Research Institute 555 Mission Bay Blvd South Box 3118, Room 252K San Francisco, CA 94158-9001 [email protected] Key words: Genetics Pathogenesis Classification Mutation Nevi Table of Contents Molecular pathogenesis of melanocytic neoplasia .................................................... 1 Classification of melanocytic neoplasms
    [Show full text]
  • A Search for CDKN2A/P16ink4a Mutations in Melanocytic Nevi from Patients with Melanoma and Spouse Controls by Use of Laser-Captured Microdissection
    STUDY A Search for CDKN2A/p16INK4a Mutations in Melanocytic Nevi From Patients With Melanoma and Spouse Controls by Use of Laser-Captured Microdissection Hao Wang, MD, PhD; Richard B. Presland, PhD; Michael Piepkorn, MD, PhD Objective: To determine the frequency at which the CDKN2A were observed in any of the melanocytic CDKN2A coding region is mutated in the atypical nevi nevi. of persons with sporadic melanoma. Conclusions: Point mutations in CDKN2A are an un- Design: DNA samples, isolated by laser-captured mi- common event in the atypical nevi of persons with mela- crodissection of atypical nevi from 10 patients with newly noma. As such, the data may support a hypothesis of incident cases of sporadic melanoma and their spouses melanocytic nevus histogenesis, in which the melano- as matched controls, were used as templates for nested cytic nevus and malignant melanoma represent sepa- polymerase chain reaction amplification of CDKN2A rate, pleiotropic pathways resulting from common stimuli, exons 1 and 2. such as genomic damage from UV radiation. Results: No point mutations in the coding region of Arch Dermatol. 2005;141:177-180 ONCEPTUAL MODELS OF messenger RNA are expressed at seem- melanoma development ingly normal levels in atypical as well as ba- and progression incorpo- nal nevi, but at significantly reduced lev- rate common and atypi- els in many melanomas, including the cal (dysplastic) nevi as po- earliest recognizable stage, melanoma in Ctential stages in the evolution of the situ.3-5 Moreover, the phenotype of mul- malignant phenotype in melanocytic sys- tiple and/or enlarged nevi does not geneti- tems.1 Support for this hypothesis can be cally segregate with, nor readily link by found, among other lines of evidence, in the polymorphic markers to, the CDKN2A lo- 6,7 spatial coexistence of melanoma and nevi cus.
    [Show full text]
  • Genomic Copy Number Analysis of a Spectrum of Blue Nevi Identifies
    Modern Pathology (2016) 29, 227–239 © 2016 USCAP, Inc All rights reserved 0893-3952/16 $32.00 227 Genomic copy number analysis of a spectrum of blue nevi identifies recurrent aberrations of entire chromosomal arms in melanoma ex blue nevus May P Chan1,2, Aleodor A Andea1,2, Paul W Harms1,2, Alison B Durham2, Rajiv M Patel1,2, Min Wang1, Patrick Robichaud2, Gary J Fisher2, Timothy M Johnson2 and Douglas R Fullen1,2 1Department of Pathology, University of Michigan, Ann Arbor, MI, USA and 2Department of Dermatology, University of Michigan, Ann Arbor, MI, USA Blue nevi may display significant atypia or undergo malignant transformation. Morphologic diagnosis of this spectrum of lesions is notoriously difficult, and molecular tools are increasingly used to improve diagnostic accuracy. We studied copy number aberrations in a cohort of cellular blue nevi, atypical cellular blue nevi, and melanomas ex blue nevi using Affymetrix’s OncoScan platform. Cases with sufficient DNA were analyzed for GNAQ, GNA11, and HRAS mutations. Copy number aberrations were detected in 0 of 5 (0%) cellular blue nevi, 3 of 12 (25%) atypical cellular blue nevi, and 6 of 9 (67%) melanomas ex blue nevi. None of the atypical cellular blue nevi displayed more than one aberration, whereas complex aberrations involving four or more regions were seen exclusively in melanomas ex blue nevi. Gains and losses of entire chromosomal arms were identified in four of five melanomas ex blue nevi with copy number aberrations. In particular, gains of 1q, 4p, 6p, and 8q, and losses of 1p and 4q were each found in at least two melanomas.
    [Show full text]
  • Blue Nevi and Melanomas Natural Blue BLUE NEVUS Blue Nevus (BN)
    KJ Busam, M.D. Paris, 2017 Blue Nevi and Melanomas Natural Blue BLUE NEVUS Blue Nevus (BN) • Spectrum of blue nevi – Common, Sclerosing, Epithelioid, Cellular, Plaque type blue nevi • Differential diagnosis – Melanoma ex BN or simulating BN – BN vs other tumors – Biphenotypic/collision lesions Common Blue Nevus Clinical: - Circumscribed small bluish macule/papule - Preferred sites: Scalp, wrist, foot Pathology: - Predominantly reticular dermal lesion - Pigmented fusiform and dendritic cells - Admixed melanophages - Bland cytology Common Blue Nevus Blue Nevus Sclerosing Blue Nevus Pigm BN Cellular Blue Nevus - 49 yo woman - Buttock nodule CBN Cellular Blue Nevus Thrombi and stromal edema Multinucleated giant melanocytes Cellular Blue Nevus Hemorrhagic cystic (“aneurysmal”) change Amelanotic Cellular Blue Nevus 19 yo man with buttock lesion Atypical CBN Plaque-Type Blue Nevus Plaque-type Blue Nevus Plaque Type Blue Nevus Mucosal Blue Nevus Conjunctival Blue Nevus Nodal Blue Nevus Combined epithelioid BN Blue Nevus • M Tieche 1906; Virchow Arch Pathol Anat “Blaue Naevus” • B Upshaw 1947; Surgery “Extensive Blue Nevus” (plaque-type BN) • A Allen 1949; Cancer “ Cellular Blue Nevus” Blue Nevus – Mutation Analysis Type of Lesion GNAQ GNA11 Number Common BN 6.7% 65% 60 Cellular BN 8.3% 72.2% 36 Amelanotic BN 0% 70% 10 Nevus of Ota 5% 10% 20 Nevus of Ito 16.7% 0% 7 TOTAL 6.5% 55% 139 Van Raamsdonk et al NEJM 2010; 2191-9 Blue Nevus – Mutation Analysis Type of Blue Nevus GNAQ Number Common Blue Nevus 40% 4/10 Cellular Blue Nevus 44% 4/9 Hypomelanotic
    [Show full text]
  • Incidence of New and Changed Nevi and Melanomas Detected Using Baseline Images and Dermoscopy in Patients at High Risk for Melanoma
    STUDY Incidence of New and Changed Nevi and Melanomas Detected Using Baseline Images and Dermoscopy in Patients at High Risk for Melanoma Jeremy P. Banky, MBBS; John W. Kelly, MDBS; Dallas R. English, PhD; Josephine M. Yeatman, MBBS, FACD; John P. Dowling, MBBS, FRCPA Objective: To determine the incidence of new, changed, Results: The incidence of new, changed, and regressed and regressed nevi and melanomas in a cohort of pa- nevi decreased with increasing age (PϽ.001), whereas tients at high risk for melanoma using baseline total body the incidence of melanomas increased (P=.05). The num- photography and dermatoscopy. ber of dysplastic nevi at baseline was positively associ- ated with the incidence of changed nevi (PϽ.001) and Design: Cohort study of patients at high risk for mela- melanomas (P=.03). The use of baseline photography and noma who underwent baseline cutaneous photography dermatoscopy was associated with low biopsy rates and between January 1, 1992, and December 31, 1997, and early detection of melanomas. The development of mela- had at least 1 follow-up visit by December 31, 1998. noma in association with a preexisting nevus was not di- rectly correlated with a change in a preexisting lesion Setting: Private practice rooms of 1 dermatologist in con- monitored by baseline photography. junction with a public hospital-based, multidisciplinary melanoma clinic in Victoria, Australia. Conclusions: Nevi are dynamic, and only a small per- centage of all new and changed melanocytic lesions are Patients: A total of 309 patients who had at least 1 of the following risk factors for melanoma: personal his- melanomas.
    [Show full text]
  • S100A6 Protein Expression Is Different in Spitz Nevi and Melanomas Adriana Ribé, M.D., Ph.D., N
    S100A6 Protein Expression is Different in Spitz Nevi and Melanomas Adriana Ribé, M.D., Ph.D., N. Scott McNutt, M.D. Dermatopathology Division, Department of Pathology, New York Presbyterian Hospital—Cornell University Weill Medical College, New York, New York and melanomas, without differences. In summary, The Spitz nevus is a benign melanocytic lesion that a simple immunohistochemical test for S100A6 pro- can be identified reliably in many cases by conven- tein differentiated between Spitz nevi, melanomas, tional histopathological criteria. However, there are and melanocytic nevi. This marker could be used subsets of Spitz nevi and of malignant melanoma when the distinction is very difficult or controver- that closely resemble each other and represent di- sial in routine studies, especially when there is a agnostic challenges. S100 proteins are of interest junctional component. Further molecular analyses because of their involvement in neoplastic pro- of the S100A6 protein and gene should be per- cesses and their genes are clustered in chromosome formed to study the underlying genetic bases for 1q21. Chromosome 1 contains mutations in several such differences. types of tumors, including melanomas. The expres- sion of different S100 proteins (A2, A6 and A8/A9 or KEY WORDS: Melanocyte, Melanoma, S100, A12) was examined in 42 Spitz nevi, 105 melano- S100A6, Spindle and epithelioid cell nevus, Spitz mas, and 73 melanocytic nevi to test the hypothesis nevus. that their expression differs among these entities Mod Pathol 2003;16(5):505–511 and may contribute to the distinction between these entities. The results showed an up-regulation of The epithelioid and spindle cell nevus was first S100A6 protein in Spitz nevi, melanomas, and mela- described in 1948 by Spitz and named juvenile mel- nocytic nevi but with a different percentage of pos- anoma (1).
    [Show full text]
  • Melanoma Biomarkers and Their Potential Application for in Vivo Diagnostic Imaging Modalities
    International Journal of Molecular Sciences Review Melanoma Biomarkers and Their Potential Application for In Vivo Diagnostic Imaging Modalities 1,2, 3, 1 1 1,2 Monica Hessler y , Elmira Jalilian y, Qiuyun Xu , Shriya Reddy , Luke Horton , Kenneth Elkin 1,2, Rayyan Manwar 1,4 , Maria Tsoukas 5, Darius Mehregan 2 and Kamran Avanaki 4,5,* 1 Department of Biomedical Engineering, Wayne State University, Detroit, MI 48201, USA; [email protected] (M.H.); [email protected] (Q.X.); [email protected] (S.R.); [email protected] (L.H.); [email protected] (K.E.); [email protected] (R.M.) 2 Department of Dermatology, School of Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA; [email protected] 3 Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA; [email protected] 4 Richard and Loan Hill Department of Bioengineering, University of Illinois at Chicago, Chicago, IL 60607, USA 5 Department of Dermatology, University of Illinois at Chicago, Chicago, IL 60607, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-312-413-5528 These authors have contributed equally. y Received: 3 September 2020; Accepted: 12 December 2020; Published: 16 December 2020 Abstract: Melanoma is the deadliest form of skin cancer and remains a diagnostic challenge in the dermatology clinic. Several non-invasive imaging techniques have been developed to identify melanoma. The signal source in each of these modalities is based on the alteration of physical characteristics of the tissue from healthy/benign to melanoma. However, as these characteristics are not always sufficiently specific, the current imaging techniques are not adequate for use in the clinical setting.
    [Show full text]
  • Melanocytic Nevi and Melanoma: Unraveling a Complex Relationship
    Oncogene (2017), 1–22 © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-9232/17 www.nature.com/onc REVIEW Melanocytic nevi and melanoma: unraveling a complex relationship WE Damsky1 and M Bosenberg1,2 Approximately 33% of melanomas are derived directly from benign, melanocytic nevi. Despite this, the vast majority of melanocytic nevi, which typically form as a result of BRAFV600E-activating mutations, will never progress to melanoma. Herein, we synthesize basic scientific insights and data from mouse models with common observations from clinical practice to comprehensively review melanocytic nevus biology. In particular, we focus on the mechanisms by which growth arrest is established after BRAFV600E mutation. Means by which growth arrest can be overcome and how melanocytic nevi relate to melanoma are also considered. Finally, we present a new conceptual paradigm for understanding the growth arrest of melanocytic nevi in vivo termed stable clonal expansion. This review builds upon the canonical hypothesis of oncogene-induced senescence in growth arrest and tumor suppression in melanocytic nevi and melanoma. Oncogene advance online publication, 12 June 2017; doi:10.1038/onc.2017.189 INTRODUCTION oncogene-induced senescence (OIS). The concept of OIS is based Growth arrest after activation of individual oncogenes can prevent on the phenomenon of replicative senescence (RS), a process cancer formation. Melanocytic nevi are neoplasms resulting from during which cultured cells cease proliferation after a finite 1,2 the proliferation of melanocytes, the normal pigment-producing number of passages in vitro. During RS, cells lose the ability to 3 cells in the skin. Nevi are growth arrested, clonal neoplasms of re-enter the cell cycle, even in the presence of mitogenic stimuli.
    [Show full text]
  • Spitz Nevi and Atypical Spitz Nevi/Tumors: a Histologic and Immunohistochemical Analysis
    Modern Pathology (2005) 18, 197–204 & 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis Payal Kapur1, M Angelica Selim2, Lonnie C Roy3, Mani Yegappan1, Arthur G Weinberg1,3 and Mai P Hoang1,3 1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; 2Duke University Medical Center, Durham, NC, USA and 3Children’s Medical Center, Dallas, TX, USA A subset of Spitz nevi poses substantial diagnostic difficulty, even among experts, due to its resemblance to malignant melanoma. These lesions are termed atypical Spitz nevi/tumors and there is currently a lack of objective criteria for predicting their biologic behavior. We compared the expression of Ki-67, p21, and fatty acid synthase by immunohistochemistry in 10 atypical Spitz nevi, 28 typical Spitz nevi, 19 compound melanocytic nevi and 18 invasive malignant melanomas. There was a progressive increase in fatty acid synthase cytoplasmic expression with statistically significant differences observed between Spitz nevi and atypical Spitz nevi (P ¼ 0.003) and between atypical Spitz nevi and malignant melanoma (Po0.050). Ki-67 nuclear staining was lower in both typical and atypical forms of Spitz lesions than in malignant melanoma (Po0.001). The degree of P21 nuclear expression in atypical Spitz nevi was not significantly different than in Spitz nevi, but was significantly greater than expression in conventional nevi and approached significance after multiple comparisons corrections for malignant melanoma. Thus, a high level of P21 expression makes a tumor more likely to be a typical or atypical Spitz nevus than a malignant melanoma, especially when coupled with a low Ki-67 index and weak expression of fatty acid synthase.
    [Show full text]
  • Choroidal Melanocytic Lesions
    TODAY’S PRACTICE CLINICAL PEARLS Choroidal and Retinal Tumors in Adults: Choroidal Melanocytic Lesions Part two of a four-part series on guidelines for diagnosing and treating ocular lesions. BY TERESA DIAGO, MD; LUIS AMSELEM, MD; AND JOSE S. PULIDO, MD, MPH, MS, MBA n the first article of this series (Choroidal and Retinal Tumors in Adults: Vascular Tumors of the Retina, June 2011, page 76), we discussed vascular tumors of the retina. In this second article, we describe the clinical Ifeatures, diagnosis, and treatment of three types of choroidal melanocytic lesions. CHOROIDAL NEVUS Choroidal nevus (Figure 1), the most common pri- mary intraocular tumor,1 is a benign tumor that arises from melanocytic cells derived from the neural crest. Choroidal nevi are more common in white people, with 4% of the population having at least one.1 Malignant transformation into melanoma is possible; therefore, choroidal nevi should be monitored even though the rate is 1 in 4,000.2 As noted below, certain risk factors are associated with a higher risk of transformation. Clinical features. Most choroidal nevi are congeni- tal, but they usually do not become pigmented and Figure 1. Choroidal nevus. clinically detectable until after childhood. They can be pigmented, amelanotic, or partially pigmented. ments and to determine acoustic hollowness, a prog- Although the majority of choroidal nevi are asympto- nostic factor that is associated with the nevus possibly matic, approximately 11%, either subfoveal or located being malignant. near the fovea, become symptomatic later due to sub- Differential diagnoses. The differential diagnoses of retinal fluid and choroidal neovascularization.3 choroidal nevus include choroidal melanoma, metastat- Diagnostic approaches.
    [Show full text]